Drug Labeling Status of Culprit Drugs Inducing Severe Cutaneous Adverse Reactions
Journal of Pharmacoepidemiology and Risk Management · 2021
DOI: 10.56142/2021.13.2.70 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacoepidemiology and Risk Management, 2021. Verfasst von Hui Jong Yeom und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Hui Jong Yeom,BPharm, Hyun Hwa Kim,BPharm, Hyun Jee Kim,MS, Soobeen Park,BPharm, Ji Young Jang,BPharm, Ga-Yoon Park,MD, Dong Yoon Kang, MD, PhD and Hye-Ryun Kang, MD, PhD. Journal of Pharmacoepidemiology and Risk Management 2021;13:70-7. https://doi.org/10.56142/2021.13.2.70
Zitieren
APA
Yeom, H. J., Kim, H. H., Kim, H. J., Park, S., Jang, J. Y., Park, G., Kang, D. Y., & Kang, H. (2021). Drug Labeling Status of Culprit Drugs Inducing Severe Cutaneous Adverse Reactions. Journal of Pharmacoepidemiology and Risk Management. https://doi.org/10.56142/2021.13.2.70
Vancouver
Yeom HJ, Kim HH, Kim HJ, Park S, Jang JY, Park G, et al. Drug Labeling Status of Culprit Drugs Inducing Severe Cutaneous Adverse Reactions. Journal of Pharmacoepidemiology and Risk Management. 2021. doi:10.56142/2021.13.2.70
BibTeX
@article{Yeom2021,
author = {Yeom, Hui Jong and Kim, Hyun Hwa and Kim, Hyun Jee and Park, Soobeen and Jang, Ji Young and Park, Ga-Yoon and Kang, Dong Yoon and Kang, Hye-Ryun},
title = {Drug Labeling Status of Culprit Drugs Inducing Severe Cutaneous Adverse Reactions},
journal = {Journal of Pharmacoepidemiology and Risk Management},
year = {2021},
doi = {10.56142/2021.13.2.70}
}
EUVIMED